Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: Results from the study of heart and renal protection

Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: Results from the study of heart and renal protection

Show other versions (1)

Bibliographic Details
Main Authors:	Reith, C, Staplin, N, Herrington, W, Stevens, W, Emberson, J, Haynes, R, Mafham, M, Armitage, J, Cass, A, Craig, J, Jiang, L, Pedersen, T, Baigent, C, Landray, M, on behalf of the SHARP Collaborative Group
Format:	Journal article
Published:	BioMed Central 2017

Similar Items

Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection
by: C. Reith, et al.
Published: (2017-05-01)

Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation
by: Storey, B, et al.
Published: (2017)

Cost-effectiveness of lowering LDL cholesterol with statins and ezetimibe in chronic kidney disease
by: Mihaylova, B, et al.
Published: (2019)

The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection.
by: Herrington, W, et al.
Published: (2014)

Effects of lowering LDL cholesterol on progression of kidney disease.
by: Haynes, R, et al.
Published: (2014)

Use of causal diagrams to inform the analysis and interpretation of observational studies: An example from the Study of Heart and Renal Protection (SHARP)
by: Staplin, N, et al.
Published: (2016)

Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials
by: Cholesterol Treatment Trialists' Collaboration, et al.
Published: (2016)

Evidence for the prevention and treatment of stroke in dialysis patients
by: Herrington, W, et al.
Published: (2014)

Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection.
by: Mafham, M, et al.
Published: (2017)

Benefits of lowering cholesterol in chronic kidney disease Reply
by: Baigent, C, et al.
Published: (2011)

Conventional and genetic evidence on the association between adiposity and chronic kidney disease
by: Zhu, P, et al.
Published: (2020)

Comparison of the accuracy and completeness of records of serious vascular events in routinely collected data vs clinical trial–adjudicated direct follow-up data in the UK: secondary analysis of the ascend randomized clinical trial
by: Harper, C, et al.
Published: (2021)

Smoking and adverse outcomes in patients With CKD: the Study of Heart and Renal Protection (SHARP)
by: Emberson, J, et al.
Published: (2016)

Efficacy and safety of more intensive lowering of LDL cholesterol Reply
by: Baigent, C, et al.
Published: (2011)

Efficacy and safety of more intensive lowering of LDL cholesterol Reply
by: Baigent, C, et al.
Published: (2011)

Cross-sectional associations between central and general adiposity with albuminuria: observations from 400,000 people in UK Biobank
by: Zhu, P, et al.
Published: (2020)

Evidence for reverse causality in the association between blood pressure and cardiovascular risk in patients with chronic kidney disease
by: Herrington, W, et al.
Published: (2016)

Estimated glomerular filtration rate and the risk of major vascular events and all-cause mortality: a meta-analysis.
by: Mafham, M, et al.
Published: (2011)

Reliability of major bleeding events in UK routine data vs clinical trial adjudicated follow-up data
by: Harper, C, et al.
Published: (2023)

Comparison of routinely collected data with clinical trial adjudicated direct follow-up: post-hoc analyses of serious cardiovascular events from the United Kingdom-based ASCEND randomized trial
by: Harper, C, et al.
Published: (2021)

Impact of CKD on household income
by: Morton, R, et al.
Published: (2017)

Impact of outcome adjudication in kidney disease trials: observations from the Study of Heart and Renal Protection (SHARP)
by: Herrington, WG, et al.
Published: (2023)

Cystatin C and risk of vascular and nonvascular mortality: a prospective cohort study of older men.
by: Emberson, JR, et al.
Published: (2010)

Evaluating the contribution of the cause of kidney disease to prognosis in CKD: results from the Study of Heart and Renal Protection (SHARP).
by: Haynes, R, et al.
Published: (2014)

Evaluating the contribution of the cause of kidney disease to prognosis in ckd: Results from the Study of Heart and Renal Protection (SHARP)
by: Haynes, R, et al.
Published: (2014)

Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (the 3C Study) – results of a randomized controlled clinical trial
by: Haynes, R, et al.
Published: (2018)

Impact of diabetes on the effects of sodium glucose co-transporter-2 (SGLT2) inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
by: Herrington, W, et al.
Published: (2022)

Apolipoprotein B, triglyceride-rich lipoproteins, and risk of cardiovascular events in persons with CKD
by: Lamprea-Montealegre, J, et al.
Published: (2019)

Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP)
by: Staplin, N, et al.
Published: (2015)

Conventional and genetic evidence on the association between adiposity and CKD
by: Zhu, P, et al.
Published: (2020)

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial
by: Staplin, N, et al.
Published: (2023)

Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy
by: Storey, B, et al.
Published: (2018)

Study of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease
by: Baigent, C, et al.
Published: (2010)

Estimated glomerular filtration rate and the risk of major vascular events and all-cause mortality: a meta-analysis.
by: Marion Mafham, et al.
Published: (2011-01-01)

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
by: Baigent, C, et al.
Published: (2010)

LDL cholesterol targets--how low to go?
by: Bulbulia, R, et al.
Published: (2012)

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
by: Baigent, C, et al.
Published: (2011)

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
by: Baigent, C, et al.
Published: (2011)

Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy.
by: Emberson, J, et al.
Published: (2012)

Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials
by: Staplin, N, et al.
Published: (2021)